EMA Authorised: RoActemra (tocilizumab) — Roche Registration GmbH

View source ↗

Summary

RoActemra (tocilizumab) has been authorised by the European Medicines Agency for multiple indications including rheumatoid arthritis, juvenile idiopathic arthri…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cytokine Release Syndrome
• Giant Cell Arteritis
• Juvenile Idiopathic Arthritis
• Rheumatoid Arthritis

Drugs mentioned

• RoActemra (tocilizumab)

Snippet

Status: Authorised. Therapeutic area: Arthritis, Rheumatoid;Arthritis, Juvenile Rheumatoid;Cytokine Release Syndrome;Giant Cell Arteritis;COVID-19 virus infection. MAH: Roche Registration GmbH. Decision date: 12/02/2026